<DOC>
	<DOCNO>NCT01824303</DOCNO>
	<brief_summary>The purpose study determine LiRIS® , investigational drug-delivery system , safe tolerable woman Interstitial Cystitis ( IC ) , evaluate change IC symptom follow LiRIS administration .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Study LiRIS® 400 mg Women With Interstitial Cystitis</brief_title>
	<detailed_description>The study conduct 2 part : randomize , blind part subject assign randomly ( chance ) LiRIS 400 mg LiRIS placebo ; subject complete part eligible continue , may participate open-label part subject receive LiRIS 400 mg . In part study ( blind open-label ) , LiRIS insert bladder cystoscopy , remain bladder 14 day , remove cystoscopy . In addition 14 day period LiRIS/LiRIS Placebo , screen period 2 week follow period 4 week .</detailed_description>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Inclusion Criteria Blinded study : Women age 18 Diagnosed Interstitial Cystitis define protocol Able report IC symptom bladder pain , void habit , require protocol , record diary Able comply visit schedule diary completion home Openlabel Extension : Must complete blind study prior screen Openlabel extension Exclusion Criteria ( Blinded OpenLabel Extension ) : Pregnant lactate woman History presence condition would make difficult accurately evaluate bladder symptom Bladder urethral abnormality would prevent safe insertion investigational product Requiring medication allow per study protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>